Reumatologia Clinica最新文献

{"title":"Tratamiento exitoso de la granulomatosis eosinofílica con poliangeítis con metotrexato y dosis bajas de mepolizumab","authors":"Luis Francisco Valdés-Corona , Patricia Aguilar-Dominguez , Ariel Jasqui-Bucay , Mariana Arroyo-Machiavelo","doi":"10.1016/j.reuma.2024.09.003","DOIUrl":"10.1016/j.reuma.2024.09.003","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 10","pages":"Pages 571-572"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis","authors":"Burak Okyar ,&nbsp;Servet Yüce ,&nbsp;İbrahim Halil Bilen ,&nbsp;Bekir Torun ,&nbsp;İlyas Öztürk ,&nbsp;Gözde Yıldırım Çetin","doi":"10.1016/j.reuma.2024.09.006","DOIUrl":"10.1016/j.reuma.2024.09.006","url":null,"abstract":"<div><h3>Introduction</h3><div>AS is a chronic disease with an inflammatory serum microenvironment characterized by increased oxidative stress (OS). Along with OS, reactive oxygen species (ROS) are elevated in patients with AS. Overexpression of ROS causes active inflammatory processes leading to the secretion of pro-inflammatory factors, including tumor necrosis factor-alpha (TNF-α). Immature granulocytes (IG) are essential to the chronic inflammatory process. This may mean that IG can be a parameter used in the follow-up of chronic inflammatory diseases such as AS.</div></div><div><h3>Objective</h3><div>We aimed to evaluate the change in IG in patients with AS who were on biologic medication for six months after diagnosis and to assess its relationship with disease activity, remission, and BASDAI score.</div></div><div><h3>Methods</h3><div>This single-center, retrospective study was conducted between January 2020 and January 2022. For the study, 68 patients were included in the patient group and 74 patients in the control group. Demographic and laboratory data were recorded and compared in the groups. Then, the patient group was divided into two groups: pre-biologic drug and post-biologic drug. Hemogram data, IG, ESR, CRP, and BASDAI data were recorded for both groups. Correlation analysis was performed between the results of IG data and hemogram and laboratory data.</div></div><div><h3>Conclusion</h3><div>In our study, WBC, neutrophil, IG, and IG% ratios were significantly higher in AS patients compared to the control group. Neutrophil, IG, and IG% levels were significantly decreased in the AS group compared to pretreatment and post-treatment comparisons. In addition, IG levels were correlated with WBC, neutrophil, CRP, and ESR levels. This study hypothesized that IG values may be a valuable parameter for monitoring AS disease severity, response to treatment, and disease activation after biological drug use.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 10","pages":"Pages 533-538"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vacunación contra virus de papiloma humano en pacientes con enfermedades inmunomediadas","authors":"Marco Tobar-Marcillo ,&nbsp;Carlos Guerrero-Solís ,&nbsp;Daniel Goyes-Burbano ,&nbsp;Jorge Esteban Toro-Tobar","doi":"10.1016/j.reuma.2024.08.001","DOIUrl":"10.1016/j.reuma.2024.08.001","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 10","pages":"Page 570"},"PeriodicalIF":1.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The “target sign”: A hallmark of lupus enteritis","authors":"Adriana C. Esteves ,&nbsp;Beatriz Mendes ,&nbsp;Helena Assunção ,&nbsp;Luís Inês","doi":"10.1016/j.reuma.2024.08.004","DOIUrl":"10.1016/j.reuma.2024.08.004","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 515-516"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A detailed quantitative analysis of circulating T peripheral and follicular helper lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus","authors":"Raquel Sánchez-Gutiérrez ,&nbsp;Marlen Vitales-Noyola ,&nbsp;Larisa González-Baranda ,&nbsp;Diana P. Portales-Pérez ,&nbsp;Esther Layseca-Espinosa ,&nbsp;Mariana H. García-Hernández ,&nbsp;Roberto González-Amaro","doi":"10.1016/j.reuma.2024.07.002","DOIUrl":"10.1016/j.reuma.2024.07.002","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Peripheral and follicular helper T lymphocytes (Tph and Tfh, respectively) have an important role in B cell immune responses and the pathogenesis of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Although several studies on the number of Tph and Tfh cells in these conditions have been published, different phenotypes have been employed for their analysis. In this study, we assessed the levels and function of Tph and Tfh cells in blood samples from patients with RA and SLE by using an extended immunophenotype.</div></div><div><h3>Materials and methods</h3><div>In a cross-sectional pilot study, blood samples from twenty-seven patients with RA and fifteen with SLE, and twenty-six healthy controls were studied. The levels of Tph (CD4⁺PD-1⁺CXCR5⁻CD38⁺CD69⁺ICOS⁺) and Tfh (CD4⁺PD-1⁺CXCR5⁺CD38⁺CD69⁺ICOS⁺) cells were analyzed by flow cytometry. In addition, the function of Tph/Tfh cells was estimated by measuring the synthesis of IL-21 by these lymphocytes as well as the number of circulating plasmablasts (CD19⁺CD27⁺CD20⁻CD38^hi).</div></div><div><h3>Results</h3><div>Increased percentages of Tph and Tfh lymphocytes were detected in patients with RA and SLE. Furthermore, the synthesis of IL-21 tended to be higher in both conditions, and higher levels of plasmablasts were detected in these patients, compared to controls. In patients with SLE, the number of Tph cells was associated with disease activity and with the levels of circulating plasmablasts, whereas in patients with RA a significant correlation between Tph cells and evolution time was observed.</div></div><div><h3>Discussion and conclusions</h3><div>Our data of Tph and Tfh lymphocytes, based in the analysis of an extended phenotype of these cells, provides further evidence on their involvement in the pathogenesis of RA and SLE.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 476-483"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-B*51:01 in Iranian patients with Behcet uveitis syndrome","authors":"Zahra Hoseini ,&nbsp;Fatemeh Rezaei Rad ,&nbsp;Mohammad Zarei ,&nbsp;Nazanin Ebrahimiadib ,&nbsp;Zahra Salimian ,&nbsp;Mahdi Zamani","doi":"10.1016/j.reuma.2024.07.001","DOIUrl":"10.1016/j.reuma.2024.07.001","url":null,"abstract":"<div><h3>Background</h3><div>Behcet's disease (BD) is a multisystem disorder prevalent along the historic Silk Road, with Behcet's uveitis (BU) representing a significant complication contributing to disability. Various studies have linked different HLA alleles with BD across diverse populations.</div></div><div><h3>Methods</h3><div>In this study, we investigated the association between HLA-B51:01/x and HLA-B27/x genotypes with Behcet's uveitis in 50 unrelated Iranian patients diagnosed with Behcet's uveitis, comparing them to a control group of 70 healthy individuals. Our analysis aimed to determine the susceptibility conferred by these alleles and assess their clinical relevance.</div></div><div><h3>Results</h3><div>Our findings indicate a notable susceptibility conferred by the HLA-B51:01/x genotype for Behcet's uveitis (<em>P</em> <!-->=<!--> <!-->0.0001). Conversely, the B27/x genotype did not demonstrate significant associations with Behcet's uveitis. Furthermore, we employed prevalence-corrected positive predictive value (PcPPV) calculations to gauge the clinical utility of testing for these alleles within the Iranian Behcet's uveitis patient population. The PcPPV for B27/x genotype testing was determined to be 0.05%, while the PcPPV for B51:01/x genotype testing in the same population was 0.065%. These results suggest that carriers of the B*51:01 allele, when presenting with clinical symptoms, exhibit a heightened risk for Behcet's uveitis compared to the general population.</div></div><div><h3>Conclusion</h3><div>Individuals carrying the B51:01 allele, when symptomatic, face an elevated Behcet's uveitis risk. This insight aids in targeted clinical assessments for at-risk populations.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 470-475"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación de la eficacia y seguridad de la terapia gravitacional en una cohorte de pacientes con esclerosis sistémica","authors":"Luisa Fernanda Servioli ,&nbsp;Eugenia Isasi ,&nbsp;Alejandra Pérez ,&nbsp;Silvia Pouquette ,&nbsp;María Eloísa Isasi","doi":"10.1016/j.reuma.2024.07.006","DOIUrl":"10.1016/j.reuma.2024.07.006","url":null,"abstract":"<div><h3>Background</h3><div>The exposure to artificial gravity (AG) through human centrifugation is the basis of the treatment called gravity therapy (GT), in which the mechanical stimulation over the vessel wall, induces the synthesis and release of prostacyclin. It has been used for more than four decades in Uruguay in the treatment of different vascular-based pathologies. In patients with systemic sclerosis (SSc) it has shown good benefits and excellent safety profile over the years. However, there is a lack of knowledge in the scientific community about GT and its results.</div></div><div><h3>Objective</h3><div>To evaluate the effectiveness of GT in cutaneous and vascular involvement, in the quality of life and functional capacity and its safety profile in patients with SSc.</div></div><div><h3>Methodology</h3><div>It is a descriptive and retrospective study of patients with SSc assisted in an autoimmunity center in Montevideo, treated with GT in the last 10<!--> <!-->years.</div></div><div><h3>Results</h3><div>Fifty patients were included, 48 women (96%) and 2 men (4%) with a mean age of 62<!--> <!-->±<!--> <!-->12 years. The mean time of evolution of SSc at the time of inclusion in the study at the beginning of GT was 6.8<!--> <!-->±<!--> <!-->3.2 years and 2.8<!--> <!-->±<!--> <!-->3.2 years respectively. After GT, a significant improvement in the modified Rodnan skin score (mRSS) was observed (pre-GT 19.2<!--> <!-->±<!--> <!-->8.7 vs post-GT 5.4<!--> <!-->±<!--> <!-->5.0, <em>P</em> <!-->&lt;<!--> <!-->.05), which was not related to the time of disease progression at the beginning of GT nor to the skin extension or immunological profile. The degree of improvement post-GT was related to a higher initial mRSS (R<!--> <!-->=<!--> <!-->0.84, <em>P</em> <!-->&lt;<!--> <!-->.05). Also, a significant improvement was observed in the number of patients with puffy fingers (pre-GT 50% vs post-GT 20% patients, <em>P</em> <!-->&lt;<!--> <!-->.05), but not in telangiectasias, pitting scars or sclerodactyly. The severity of Raynaud's phenomenon significantly decreased (pre-GT: grade 3-4, 43/48 (89.6%) patients vs post-GT: grade ≤<!--> <!-->2, 42/47 (89.4%) patients, <em>P</em> <!-->&lt;<!--> <!-->.05) as well as the vascular pain measured with VAS (0-10 scale) (pre-GT: 7.6<!--> <!-->±<!--> <!-->2.2 vs post-TG: 1.4<!--> <!-->±<!--> <!-->1.2, <em>P</em> <!-->&lt;<!--> <!-->.05). The healing of digital ulcers was also recorded. Regarding the results reported by patients, 97% reported improvement in the quality of life and 89.5% improvement in the ability to carry out activities of daily living. No significant adverse effects were recorded.</div></div><div><h3>Conclusions</h3><div>GT improved cutaneous and vascular involvement, the quality of life and the functional capacity in patients with SSc with an excellent safety profile. Randomized, controlled clinical trials are needed to corroborate these observational results.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 463-469"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fabry disease in familial Mediterranean fever according to the severity of the disease","authors":"Sadettin Uslu ,&nbsp;Gökhan Kabadayi ,&nbsp;Pelin Teke Kısa ,&nbsp;Tuba Yüce Inel ,&nbsp;Zümrüt Arslan ,&nbsp;Nur Arslan ,&nbsp;Servet Akar ,&nbsp;Fatos Onen ,&nbsp;Ismail Sari","doi":"10.1016/j.reuma.2024.09.002","DOIUrl":"10.1016/j.reuma.2024.09.002","url":null,"abstract":"<div><h3>Objectives</h3><div>Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness.</div></div><div><h3>Methods</h3><div>Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept.</div></div><div><h3>Results</h3><div>FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 484-489"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guías de Práctica Clínica para el tratamiento del lupus eritematoso sistémico del Colegio Mexicano de Reumatología. Actualización 2024","authors":"Lilia Andrade-Ortega ,&nbsp;Daniel Xibillé-Friedmann ,&nbsp;Dionicio A. Galarza-Delgado ,&nbsp;Miguel Ángel Saavedra ,&nbsp;José Alvarez-Nemegyei ,&nbsp;Mary-Carmen Amigo-Castañeda ,&nbsp;Hilda Fragoso-Loyo ,&nbsp;María Vanessa Gordillo-Huerta ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Luis Javier Jara-Quezada† ,&nbsp;Javier Merayo-Chalico ,&nbsp;Margarita Portela-Hernández ,&nbsp;Sandra Sicsik-Ayala ,&nbsp;Carlos Abud-Mendoza ,&nbsp;Deshire Alpizar-Rodriguez ,&nbsp;José Luis Amaya-Estrada ,&nbsp;Yaneth R. Barragán-Navarro ,&nbsp;Sandra M. Carrillo-Vázquez ,&nbsp;Zully Castro-Colín ,&nbsp;Luis Javier Cruz-Álvarez ,&nbsp;Leonor A. Barile-Fabris","doi":"10.1016/j.reuma.2024.07.004","DOIUrl":"10.1016/j.reuma.2024.07.004","url":null,"abstract":"<div><div>Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system.</div><div>We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 490-510"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalencia del entesofito occipital en enfermedades reumáticas inflamatorias y no inflamatorias","authors":"Natalia de la Torre Rubio,&nbsp;Jose Campos Esteban,&nbsp;José Luis Andréu Sánchez,&nbsp;Jesús Sanz Sanz","doi":"10.1016/j.reuma.2024.06.004","DOIUrl":"10.1016/j.reuma.2024.06.004","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 513-514"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}